Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer.

Saved in:
Bibliographic Details
Title: Innovative therapeutic cancer vaccine PDClung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer.
Authors: Vansteenkiste J; Respiratory Oncology Unit (Pulmonology), University Hospitals Leuven, Leuven, Belgium. Electronic address: johan.vansteenkiste@uzleuven.be., Demedts I; Pulmonary Diseases, AZ Delta Campus Rumbeke, Roeselare, Belgium., Cuppens K; Pulmonology & Thoracic Oncology Department, Jessa Hospital, Hasselt, Belgium., Pons-Tostivint E; Medical Oncology Department, Nantes University Hospital, Nantes, France., Wauters E; Respiratory Oncology Unit (Pulmonology), University Hospitals Leuven, Leuven, Belgium., Borm FJ; Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands., Sibille A; Department of Pulmonology, Centre Hospitalier Universitaire de Liège, Liège, Belgium., Colinet B; Pneumology Department, GHdC, Grand Hôpital de Charleroi, Site Notre Dame, Charleroi, Belgium., Pérol M; Medical Oncology Department, Centre Léon Bérard, Lyon, France., Theelen WSME; Thoracic Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Biesma B; Pulmonology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Van De Kerkhove C; Clinical Study Centre, Vitaz campus Sint-Niklaas Moerland, Sint-Niklaas, Belgium., Buchmeier E; Hematology & Oncology Department, Kliniken der Stadt Koln gGmbH, Köln, Germany., Althoff FC; Hemato-Oncology Department, Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt Am Main, Germany., Derijcke S; Pulmonology - Thoracic Oncology, AZ Groeninge, Campus Kennedylaan, Kortrijk, Belgium., Moro-Sibilot D; Thoracic Oncology, SHUPP, CHU Grenoble-Alpes, Grenoble, France., Laulagnier K; PDC(∗)line Pharma France, Grenoble, France., Halioua E; PDC(∗)line Pharma Belgique, Liège, Belgium., Levy L; PDC(∗)line Pharma France, Grenoble, France., Genin M; RLM Consulting, Louvain-la-Neuve, Belgium., Michel S; PDC(∗)line Pharma Belgique, Liège, Belgium., Dedry C; PDC(∗)line Pharma Belgique, Liège, Belgium., Duchayne C; PDC(∗)line Pharma Belgique, Liège, Belgium., Collodoro M; PDC(∗)line Pharma Belgique, Liège, Belgium., Renard F; PDC(∗)line Pharma Belgique, Liège, Belgium., Adriaenssens S; PDC(∗)line Pharma Belgique, Liège, Belgium., De Vos B; PDC(∗)line Pharma Belgique, Liège, Belgium., Cantero F; PDC(∗)line Pharma Belgique, Liège, Belgium., Plumas J; PDC(∗)line Pharma Belgique, Liège, Belgium., Skrzypski M; Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.
Source: ESMO open [ESMO Open] 2025 Nov; Vol. 10 (11), pp. 105844. Date of Electronic Publication: 2025 Oct 15.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2059-7029
DOI:10.1016/j.esmoop.2025.105844